Bayer's Crop Science Surge and a Shrinking Debt Load Give Analysts Fresh Conviction

Bayer's Q2 beat driven by Crop Science, with EBITDA 11% above consensus; analysts raise targets, shares climb to €49.44.

The market's verdict on Bayer's second-quarter scorecard came swiftly and decisively. Within hours of Tuesday's results, a cascade of target-price upgrades swept across the sell-side, pushing the shares to €49.44 on Wednesday — a 2.15 percent advance — as investors digested a performance that landed comfortably ahead of consensus expectations.

The optimism is not hard to trace. UBS analyst Matthew Weston calculates that the group's core operating result ran roughly 10 percent above the market consensus for the quarter, while Deutsche Bank's Virginie Boucher-Ferte put the EBITDA surprise at 11 percent. The stock remains about 8.21 percent shy of its 52-week high of €53.86, yet the analyst community's average expectations now sit comfortably north of the €50 mark.

Crop Science Carries the Quarter

The engine of the beat was unmistakably the agriculture division. Crop Science generated second-quarter revenue of €4.910 billion, up 3.5 percent on a currency-adjusted basis, while EBITDA before special items jumped 30.2 percent to €902 million. The segment margin improved to 18.4 percent. Seed sales told a particularly encouraging story: soybean seed advanced 16.9 percent, while cotton seed — buoyed by the re-approval of the herbicide dicamba — surged 69.2 percent. Corn seed, by contrast, slipped 2.5 percent.

Group-level figures for the first half of 2026 showed revenue of €24.3 billion, a 3 percent currency-adjusted increase, with core earnings per share rising at the same pace to €3.66. EBITDA before special items climbed 7 percent to €6.6 billion. The second quarter alone delivered revenue of €10.872 billion, up 2.2 percent, with EBITDA of €2.144 billion and net income of €219 million.

The pharma division painted a more bifurcated picture. Revenue grew just 1 percent to €4.5 billion in the quarter, as the newer franchises NUBEQA and KERENDIA posted gains of 64 percent and 83 percent respectively — offsetting sharp declines at the legacy blockbusters XARELTO and EYLEA, which fell 42 percent and 33 percent as patent expiries and intensifying competition take their toll. Consumer Health contributed a more modest 1.5 percent uptick.

A Wave of Target Hikes — With One Dissenter

The analyst response was notable for its uniformity. Goldman Sachs' James Quigley lifted his price target from €62.50 to €63.50, retaining a "Buy" rating and citing the strength of the pharma franchise, progress on resolving glyphosate litigation, and what he sees as a shrinking conglomerate discount. UBS moved its target from €52 to €62, with Weston noting that the beat came through without any fresh developments on the glyphosate front — the operational momentum, in other words, is carrying the case on its own. JPMorgan's Richard Vosser upgraded the stock to "Overweight" and raised his target from €50 to €61, arguing that glyphosate risks have become more manageable. Deutsche Bank held its "Buy" rating with a €60 target, and DZ Bank lifted its fair value to €60, also keeping a buy recommendation.

The lone voice of caution comes from Jefferies, which retains a "Hold" rating with a €46 target — the bottom end of a range that now stretches from €46 to €63.50.

Legal Tailwinds and a Faster Debt Reduction

The improving operational narrative is being reinforced on two other fronts. The US Supreme Court ruled at the end of June that lawsuits alleging a missing cancer warning on the Roundup herbicide are no longer permissible under federal law — a decision that materially strengthens Bayer's hand in the long-running glyphosate litigation wave. The scheduled August 19 hearing to approve the multi-billion-dollar class settlement of $7.25 billion has been pushed back to September 10, with both sides jointly requesting the delay at a Missouri court to process opt-out requests following the Supreme Court ruling.

On the balance sheet, the picture is also brightening. Net financial debt stood at €33.6 billion at mid-year, but following a €3 billion capital injection from Apollo, Bayer has trimmed its full-year debt target to €29–30 billion — down from the previously guided €32–33 billion. That progress is tempered, however, by the continued drag of litigation payouts: free cash flow swung from €2.5 billion in the first half of last year to minus €2.7 billion in the same period this year, after minus €1.4 billion in the prior-year period. The company has left its 2026 outlook unchanged, with the next quarterly figures scheduled for November 3.